Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer

0559749 - ÚMG 2023 RIV CH eng J - Článek v odborném periodiku
Gorecki, L. - Andrš, Martin - Korábečný, J.
Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer.
Cancers (Basel). Roč. 13, č. 4 (2021), č. článku 795. E-ISSN 2072-6694
Institucionální podpora: RVO:68378050
Klíčová slova: ATR–CHK1–WEE1 axis * DNA damage response * cell-cycle checkpoints * clinical trials * inhibitors
Obor OECD: Oncology
Impakt faktor: 6.575, rok: 2021
Způsob publikování: Open access
https://www.mdpi.com/2072-6694/13/4/795

Selective killing of cancer cells while sparing healthy ones is the principle of the perfect cancer treatment and the primary aim of many oncologists, molecular biologists, and medicinal chemists. To achieve this goal, it is crucial to understand the molecular mechanisms that distinguish cancer cells from healthy ones. Accordingly, several clinical candidates that use particular mutations in cell-cycle progressions have been developed to kill cancer cells. As the majority of cancer cells have defects in G1 control, targeting the subsequent intra‑S or G2/M checkpoints has also been extensively pursued. This review focuses on clinical candidates that target the kinases involved in intra‑S and G2/M checkpoints, namely, ATR, CHK1, and WEE1 inhibitors. It provides insight into their current status and future perspectives for anticancer treatment. Overall, even though CHK1 inhibitors are still far from clinical establishment, promising accomplishments with ATR and WEE1 inhibitors in phase II trials present a positive outlook for patient survival.
Trvalý link: https://hdl.handle.net/11104/0332953